Exclusive Content
China Patent Law Amendment Review: What It Means for Pharma IP Protection
China Patent Law Amendment Review: What It Means for Pharma IP Protection The Fourth Amendment to China's 专利法 (Patent Law, zhuānlì fǎ), effective June
NMPA Priority Review Policy: What It Means for Drug Approvals in China
NMPA Priority Review Policy: What It Means for Drug Approvals in China The National Medical Products Administration (NMPA, 国家药品监督管理局, guójiā yàopǐn ji
NRDL 2026 Update Review: What It Means for Foreign Pharma in China
NRDL 2026 Update Review: What It Means for Foreign Pharma in China The 2026 revision of China’s National Reimbursement Drug List (国家医保目录, National Rei
How Bayer Achieved GMP Compliance in China: Manufacturing Case Study
How Bayer Achieved GMP Compliance in China: Manufacturing Case Study Bayer AG, the German pharmaceutical and life sciences giant, has invested over €1
How much does CCC certification cost for foreign companies?
How much does CCC certification cost for foreign companies? body{font-family:Arial,Helvetica,sans-serif;line-height:1.8;color:#333;max-width:960px;mar
How long does CCC certification take for imported products?
How long does CCC certification take for imported products? body{font-family:Arial,Helvetica,sans-serif;line-height:1.8;color:#333;max-width:960px;mar